Spyre Therapeutics Q2 loss narrower than expected; sees trial readouts in 2026

The current average analyst rating on the shares is buy. The breakdown of recommendations is 16 strong buy or buy, 1 hold and no sell or strong sell.

The median 12-month price target is $105.00, about 10.6% above the stock's August 3 closing price of $94.93.

Spyre Therapeutics said its second-quarter net loss and pretax loss were lower than analyst expectations, helped by a $40 million gain from a milestone on a prior asset sale.

The company reported a Q2 net loss of $36.20 million, compared with consensus expectations of $68.97 million from 13 analysts. Income from operations came in at -$41.64 million, versus an estimated -$74.37 million from 15 analysts. Pretax loss was $36.20 million, compared with an estimate of $70.19 million from 13 analysts.

Operating expenses were $41.64 million.